# Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults

> **NCT00472719** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 17 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** VRC-HIVADV027-00-VP
- **BIOLOGICAL:** VRC-HIVADV038-00-VP
- **BIOLOGICAL:** VRC-HIVDNA044-00-VP

## Key facts

- **NCT ID:** NCT00472719
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-07
- **Final completion:** 2013-01
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2021-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00472719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00472719, "Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00472719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*